BioNxt Solutions Reports Progress on BNT23001 Development for Multiple Sclerosis Treatment
VANCOUVER, BC / ACCESSWIRE / December 9, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience company specializing in advanced drug delivery systems, has achieved key milestones in the development of BNT23001, its proprietary sublingual thin-film (OFD) formulation of Cladribine for the treatment of Multiple Sclerosis (MS). These achievements in 2024 lay the groundwork for clinical trials and regulatory submissions in 2025, reinforcing BioNxt's commitment to advancing patient-centric therapeutic solutions.
2024 Milestones: Establishing a Strong Foundation for Cladribine Thin-Film Development
Preclinical Success: BNT23001 demonstrated high absorption rates of Cladribine through sublingual delivery in pharmacokinetic (PK) studies conducted in animal models. These studies confirmed the product's bioequivalence to the originator therapy, Mavenclad®, and validated the thin-film's rapid absorption and safety profile. Toxicity studies further demonstrated no adverse local effects, highlighting the viability of the sublingual delivery approach.
Advancements in Manufacturing: BioNxt successfully transferred the BNT23001 production process to its GMP-certified manufacturing partner, Gen-Plus GmbH & Co KG in Munich (Germany), ensuring readiness for clinical batch production. This milestone supports the Company's plan to initiate clinical trials in 2025 with reliable, high-quality product supply.
Strengthened Intellectual Property Position: A favorable International Preliminary Report on Patentability (IPRP) confirmed BNT23001's novelty, inventive step, and industrial applicability, underscoring its unique value in MS treatment. The Company has initiated patent nationalization in major jurisdictions, including Europe, the United States, and Canada, with patent grants anticipated in several regions by mid-2025.
2025 Roadmap: Advancing BNT23001 into Clinical Trials
Manufacturing Clinical Batches: BioNxt will complete GMP manufacturing and Qualified Person (QP) release of clinical trial batches in the second quarter of 2025. This step is critical for the successful initiation of human studies.
Regulatory Filings and Approvals: The Company plans to submit the Investigational Medicinal Product Dossier (IMPD) to European regulatory authorities by mid-2025, paving the way for clinical trial approval. These regulatory submissions will include data from preclinical studies and stability assessments conducted at the manufacturing site.
Clinical Study to Validate Performance: BioNxt aims to launch a pilot clinical study in the latter half of 2025. This trial will compare the efficacy, bioavailability, and safety of BNT23001 to Mavenclad®, the originator tablet product, positioning the thin-film formulation as a patient-friendly alternative.
Ongoing Patent Protection: In addition to continuing the patent nationalization process, BioNxt expects granted patents in key regions to strengthen its intellectual property portfolio and provide competitive advantages as the product moves toward commercialization.
BNT23001: Advancing Toward Clinical Validation for MS Treatment
BNT23001 offers a novel approach to MS management by addressing limitations in traditional oral therapies. Its sublingual thin-film format provides:
• Convenience: Easy-to-use and portable, ideal for patients with difficulty swallowing or active lifestyles.
• Rapid Absorption: Direct delivery through the sublingual mucosa for faster therapeutic action.
• Improved Compliance: A patient-friendly alternative designed to enhance adherence to prescribed regimens.
By delivering these advantages, BNT23001 aligns with BioNxt's mission to improve outcomes for patients living with chronic diseases like MS.
About BioNxt Solutions Inc.
BioNxt Solutions Inc. is a bioscience innovator focused on next-generation drug delivery technologies, diagnostic screening systems, and active pharmaceutical ingredient development. The Company's proprietary platforms-Sublingual (Thin-Film), Transdermal (Skin Patch), and Oral (Enteric-Coated Tablets)-target key therapeutic areas, including autoimmune diseases, neurological disorders, and longevity.
With research and development operations in North America and Europe, BioNxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. BioNxt is committed to improving healthcare by delivering precise, patient-centric solutions that enhance treatment outcomes worldwide.
BioNxt is listed on the Canadian Securities Exchange: BNXT, OTC Markets: BNXTF and trades in Germany under WKN: A3D1K3. To learn more about BioNxt, please visit www.bionxt.com.
Investor Relations & Media Contact
Hugh Rogers, Co-Founder, CEO and Director
Email: investor.relations@bionxt.com
Phone: +1 780-818-6422
Web: www.bionxt.com
LinkedIn: https://www.linkedin.com/company/bionxt-solutions
Instagram: https://www.instagram.com/bionxt
Cautionary Statement Regarding "Forward-Looking" Information
This press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding the development, testing, regulatory approval, and commercialization of BNT23001, as well as projected milestones for 2025. These statements are based on current expectations and assumptions but involve risks and uncertainties that could cause actual results to differ materially. These risks include clinical trial outcomes, regulatory delays, manufacturing challenges, intellectual property issues, market competition, and changes in laws or market conditions. The Company undertakes no obligation to update or revise forward-looking statements, except as required by law. For more information, refer to the "Risk Factors" section of the Company's filings at www.sedarplus.ca.
Trademarks: Mavenclad® is a registered trademark of EMD Serono, Inc. BioNxt Solutions Inc. is not affiliated with or endorsed by EMD Serono.
SOURCE: BioNxt Solutions Inc.
View the original press release on accesswire.com
BioNxt Solutions Inc.
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
The 13th GLA Global Logistics Conference Successfully Concludes in Bangkok, Thailand5.12.2025 16:00:00 CET | Press release
More than 2,000 logistics leaders from 130+ countries convene in Thailand to advance peace, digital innovation and trustworthy cooperation in global supply chains. SHENZHEN, CN / ACCESS Newswire / December 5, 2025 / The 13th GLA Global Logistics Conference was successfully held in Bangkok, Thailand from November 7-10, 2025, providing a prestigious international platform for business cooperation in the global logistics sector. Co-organized by the Global Logistics Enterprises Federation (GLEF) and the GLA Global Logistics Alliance, the event centered around the theme "Peaceful Prosperity, Digital Innovation, Trustworthy Cooperation." The conference brought together over 2,000 logistics professionals and industry leaders from more than 130 countries, fostering a unique environment for collaboration and knowledge exchange. With its exceptional industry influence and capacity for cross-border resource integration, GLA continues to emerge as a pivotal force in driving global supply chain inn
OMP's AI-driven Unison Planning(TM) Platform Enhances Supply Chain Agility for McCormick & Co.3.12.2025 15:00:00 CET | Press release
ATLANTA, GEORGIA / ACCESS Newswire / December 3, 2025 / OMP is helping McCormick & Co., the global leader in flavor, with an AI-driven and autonomous operational planning initiative. This partnership enables McCormick to manage both assembly-to-order (ATO) and make-to-stock (MTS) production within the Unison PlanningTM platform. The initiative tackles key challenges, including balancing ATO and MTS production on shared lines, improving inventory projections through quality-based stock releases, and managing capacity amid fluctuating demand. Addressing these challenges requires close collaboration across regions with North American and EMEA teams working in parallel, and seamless integration of SAP with the operational planning functionality within Unison Planning™. The first implementations will roll out in Canada and the United States before expanding to the EMEA and APAC regions. Through its partnership with OMP, McCormick is implementing autonomous, decision-centric planning powered
Oman's 10-Year Golden Residency Program Attracts Global Investors Seeking Stability and Long-Term Access3.12.2025 14:00:00 CET | Press release
Built for investors who value certainty, global access, and long-term confidence. MUSCAT, OM / ACCESS Newswire / December 3, 2025 / Three months after its introduction, Oman's 10-Year Golden Residency is emerging as one of the region's most compelling long-term residency pathways, attracting rising interest from investors, entrepreneurs, and internationally mobile families seeking stability, transparent regulation, and strategic access to high-growth markets. The programme-launched under Oman Vision 2040-offers a structured framework for investors wishing to establish deeper roots in a country positioning itself as a secure and globally connected economic hub.Prosperity and Liveability in Oman.jpg A contemporary Omani setting featuring growth, safety, and quality-of-life elements that define the country's reputation for prosperity and liveability. The Golden Residency grants eligible applicants long-term residency in return for a minimum investment of USD 520,000 across seven clearly d
Visit Qatar Presents Ludovico Einaudi Live in Doha3.12.2025 13:33:00 CET | Press release
DOHA, QA / ACCESS Newswire / December 3, 2025 / Visit Qatar presents one of the world's most celebrated composers and pianists, Ludovico Einaudi, to perform live in Doha on 9 January 2026 at the iconic Katara Amphitheatre. Doors open at 20:00 for an evening promising an extraordinary blend of emotion, artistry, and world-class music. Tickets are available at: https://doha.platinumlist.net/event-tickets/102626/ludovico-einaudi Known for his minimalist yet deeply evocative compositions, Ludovico Einaudi has captured global audiences with performances that seamlessly fuse classical tradition with contemporary sensibilities. His music, featured in internationally acclaimed films such as Nomadland and The Intouchables, has made him one of the most-streamed classical musicians worldwide. As Qatar continues to attract visitors from the region and around the world, the highly anticipated Ludovico Einaudi concert reflects Visit Qatar's commitment to hosting world-renowned talent and delivering
Nittetsu Mining Provides Final $1.5 Million Earn-in Payment for Camino's Los Chapitos Copper Project in Peru3.12.2025 12:00:00 CET | Press release
VANCOUVER, BC / ACCESS Newswire / December 3, 2025 / Camino Minerals Corporation (TSXV:COR)(OTC:CAMZF) ("Camino" or the "Company") is pleased to announce the receipt of the sixth, and final, CAD$1.5 million payment from its exploration partner Nittetsu Mining CO., Ltd. ("Nittetsu"), marking the successful completion of Nittetsu's earn-in expenditure requirements under the earn-in agreement dated June 13, 2023 ("Earn-In Agreement") (see news release dated June 14, 2023). Following the conclusion of the current drilling program at the Los Chapitos Copper Project ("Los Chapitos" or the "Project") in Peru, the Project will be formally converted into a joint venture, with Camino retaining a 65% participating interest, operatorship of the Project, and 50% of the life-of-mine production off-take. Los Chapitos is the second joint venture project with Nittetsu, as Camino is currently advancing the Puquios copper mine development with Nittetsu in Chile. At Los Chapitos, exploration drilling has
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom